SCHEMBL1490572

SCHEMBL1490572

CCOCc1nc2c(N)nc3cc(-c4cccc(C(=O)N5CCOCC5)c4)cnc3c2n1CC(C)(C)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.43
PLK4 O00444 1/20 0.43
JAK2 O60674 1/20 0.43
MAP4K4 O95819 1/20 0.43
ROS1 P08922 1/20 0.43
FGFR1 P11362 1/20 0.43
FLT1 P17948 1/20 0.43
MARK3 P27448 1/20 0.43
FLT4 P35916 1/20 0.43
KDR P35968 1/20 0.43
FLT3 P36888 1/20 0.43
CLK2 P49760 1/20 0.43
CSNK1G2 P78368 1/20 0.43
MAP4K2 Q12851 1/20 0.43
ROCK1 Q13464 1/20 0.43
NTRK3 Q16288 1/20 0.43
MINK1 Q8N4C8 1/20 0.43
AURKB Q96GD4 1/20 0.43
PRKD2 Q9BZL6 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1490803 0.94 TLR7 (0.50) LRRK2PLK4JAK2MAP4K4ROS1
SCHEMBL1490774 0.89 LRRK2 (0.48) LRRK2PLK4JAK2MAP4K4ROS1
SCHEMBL1490521 0.87 TLR7 (0.52) TLR7TLR8NUDT1ATR
SCHEMBL3862449 0.85 TLR7 (0.59) TLR7TLR8NUDT1
SCHEMBL1490381 0.84 PLK4 (0.46) LRRK2PLK4JAK2MAP4K4ROS1
SCHEMBL1490866 0.82 TLR7 (0.58) TLR7TLR8NUDT1
SCHEMBL1490725 0.81 TLR7 (0.56) TLR7TLR8NUDT1
SCHEMBL1490784 0.78 TLR7 (0.45) JAK2TLR7TLR8NUDT1TGFBR1
SCHEMBL3862143 0.78 TLR7 (0.61) TLR7TLR8NUDT1
SCHEMBL1490934 0.78 TLR7 (0.50) TLR7TLR8NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897609-B2 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-20070219228-A1 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-20 US disclosed
WO-2006038923-A2 ARYL SUBSTITUTED IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219228-A1 Aryl substituted imidazonaphthyridines IL2, IRF3, EIF2AK2 LRRK2 3350/4885PLK4 2914/4885JAK2 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.